Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate how effective ONTAK is in the treatment of
cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein
called CD25 on the cancer cells makes a difference in how the body responds to the treatment.
The hypothesis is that there is no difference in response rate for patients whose tumor cells
are CD25 positive or negative.
Phase:
Phase 4
Details
Lead Sponsor:
Eisai Inc.
Collaborators:
Ligand Pharmaceuticals National Cancer Institute (NCI) Tufts Medical Center